|Bid||83.25 x 1000|
|Ask||83.25 x 800|
|Day's Range||82.57 - 83.47|
|52 Week Range||52.83 - 83.47|
|Beta (3Y Monthly)||0.41|
|PE Ratio (TTM)||35.85|
|Earnings Date||Apr 30, 2019|
|Forward Dividend & Yield||2.20 (2.67%)|
|1y Target Est||85.49|
German pharma group Merck KGaA on Tuesday sidestepped the management of takeover target Versum Materials and took its $5.9 billion (4.5 billion pounds) offer directly to the U.S. chemical company's shareholders. Versum, the former speciality chemicals division of industrial gases group Air Products, has been opposed to Merck's cash offer since it was first proposed last month, saying it was committed to an all-share merger with U.S. rival Entegris agreed in January. Merck on Tuesday kept its offer price unchanged at $48 per share in cash.
Lots has changed for the South San Francisco company since it first filed its IPO plans in September: It now has a clear game plan for its drug portfolio — stretching from type 2 diabetes and the fatty liver disease NASH to cancer and a vision-blurring eye disease — and a renewed collaboration with drug giant Merck.
Germany's Merck KGaA on Tuesday said it made a full takeover bid to shareholders of Versum Materials for $48 per share, after a previous deal proposal for the same price was rejected by the U.S. target's ...
Early data of BriaCell’s combination study of lead candidate, Bria-IMT™, with KEYTRUDA® (by Merck & Co., Inc.) in advanced breast cancer will be announced at the American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Georgia, on April 3, 2019.
Hedge funds run by legendary names like George Soros and David Tepper make billions of dollars a year for themselves and their super-rich accredited investors (you’ve got to have a minimum of $1 million liquid to invest in a hedge fund) by spending enormous resources on analyzing and uncovering data about small-cap stocks that the […]
After significant hype from the mainstream media, Special Counsel Robert Mueller seemingly appeared on the verge of delivering an indictment on President Donald Trump. Instead, Mueller's report found no evidence tying Trump with Russian conspirators. That news disappointed many on the left, while simultaneously lifting prospects for Dow Jones Industrial Average and its component stocks.Although the Russia investigation, which has long dogged the Trump administration, has no direct impact on the markets, the latest news frees them from unnecessary shackles. With the president now able to concentrate on important matters, he can theoretically resume making America great again.This has positive implications for thorny issues like the U.S.-China trade war. If the White House achieves a breakthrough, we could see several Dow Jones stocks on the rise move even higher. With China harnessing the world's second-biggest economy, Wall Street will appreciate any hint of progress.InvestorPlace - Stock Market News, Stock Advice & Trading TipsIn addition, Mueller tacitly signed off on two more years of Trump. Again, the majority of Americans probably felt like they got punched in the gut. Still, we do have one bit of universal good news: we know exactly what to expect until November 2020.From a political standpoint, this is huge. Barring unusual circumstances, Trump's contentious policies such as tax or healthcare reform won't be immediately reversed. This continuity is great for the markets as it represents one less variable. * 7 Consumer Discretionary Stocks to Buy Now So with that in mind, here are five Dow Jones stocks to track on your radar: JPMorgan Chase (JPM)Source: Shutterstock Earlier this year, banking giant JPMorgan Chase (NYSE:JPM) was one of the Dow Jones stocks on the rise. However, that quickly changed this month. Since mid-March, JPM stock has dropped more than 6%. Geopolitical concerns such as icy U.S.-China relations, as well as possible trading-revenue declines have hurt prospects.But despite the troubles, JPM stock has a genuine chance of a Mueller-fueled rally. For one thing, JPMorgan is an economic bellwether: what's good for the nation is usually good for its share price. Moreover, as a banking firm, JPM receives the most benefit from a stable platform.As I alluded to earlier, it's probably not the kind of stability most people sought. Nevertheless, we generally know what to expect: strange tweets, conservative policies, and the constant push to build the wall. This predictability will at least make it easier for management to chart a path forward. Intel (INTC)Source: Shutterstock Most technology firms took a beating in the final quarter of last year, but not Intel (NASDAQ:INTC).No, INTC stock absorbed most of its pain earlier in 2018. Although usually a safe bet, Intel faced many questions regarding production delays over its next-generation chips. Amid fierce competition, many stakeholders simply gave up.Further compounding the issue, the U.S.-China trade war acted as a massive headwind. As our own Dana Blankenhorn noted last year, Intel invested substantially in Chinese infrastructure. Any hit to that region will eventually translate to volatility in INTC stock. * 5 Stocks To Buy for the Happiest Employees But this year, Intel is one of the top Dow Jones stocks on the move. Shares are already up 17% since the January opener. And with Trump no longer dealing with the Mueller investigation, he has time to wheel and deal. Although not a guarantee, INTC suddenly looks like a much-healthier prospect. Merck (MRK)Source: Shutterstock If you're looking for stocks on the rise in the Dow, you really can't go wrong with Merck (NYSE:MRK). Although the company's future is heavily tied to its cancer-fighting drug Keytruda, that hasn't stopped speculators. Indeed, if you bought MRK stock during last year's doldrums, you're living large right now.Better yet, Merck continues to ride its wave of momentum. On a year-to-date basis, MRK stock crossed into double-digit territory. For bullish traders, they don't find this status surprising. Merck maintains an enviable drug pipeline, which includes Januvia and Gardasil. Last year, they rang up $3.7 billion and $3.2 billion in sales, respectively.Plus, President Trump's rants against former President Barack Obama's healthcare policies have previously shaken the Street. Now that the Mueller investigation is out of the way, Trump has less distractions. Hopefully, he'll use this unshackling to promote positive changes for all Americans.And if not, at least we know what we're getting. Home Depot (HD)Source: Mike Mozart via Flickr (Modified)Out of all the Dow Jones stocks on the rise, my current favorite is Home Depot (NYSE:HD). Admittedly, HD stock is a bit of a cop-out. As a largely secular company -- a leaking pipe doesn't stop based on economic conditions -- HD is an "everyman" investment. No matter what, you can count on it.But that doesn't mean that Home Depot is immune to good news. Again, while most Americans may have been disappointed with the build-up to the Mueller non-announcement, it's a positive for HD. Primarily, shares do well with a robust housing market. If Trump were indicted, that would create all kinds of havoc on our economy. * 7 Reasons Why Apple Streaming Won't Move the Needle for Apple Stock At the same time, I like the fact that HD stock is a boring investment. Ultimately, it's very difficult to tell how the Street will respond to the Mueller investigation results. Therefore, sitting on HD and collecting its 2.9% dividend yield isn't a bad approach! Boeing (BA)Source: Shutterstock If you want some spice out of your Dow Jones stocks, Boeing (NYSE:BA) is it. Already under pressure from the Lion Air Flight 610 crash that killed all onboard, Boeing suffered another devastating blow: Ethiopian Airlines Flight 302 also went down under similar circumstances. Logically, BA stock tumbled badly in response.Moreover, the pain is far from over. By the looks of it, Boeing will incur significant legal costs. In both crashes, the same airplane -- the 737 Max 8 -- was involved. Additionally, the company's anti-stalling system called MCAS apparently malfunctioned on the doomed flights. If you're heavily vested in BA stock, you may want to protect yourself.But with a newly-energized President, Boeing could get its wings back. That's because Trump is still Trump, and that means more saber-rattling. Such circumstances would lift the company's military and defense divisions, an obvious welcome change.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dual-Class Stocks That Will Outperform * 7 Reasons Why Apple Streaming Won't Move the Needle for Apple Stock * 7 A-Rated Stocks to Buy in the Second Quarter Compare Brokers The post 5 Dow Jones Stocks for the End of Mueller's Investigation appeared first on InvestorPlace.
- Q4 share repurchases increased 62.8% year-over-year to a record $223.0 billion - This is the fourth consecutive quarterly record -- longest streak in the 20 years SPDJI has tracked - Total 2018 buybacks ...
NEW YORK, March 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks, you could make more than that. JustRead More...
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
The acquisition deal between Bristol-Myers and Celgene faces opposition from stakeholders of Bristol-Myers. The future of the deal depends on the outcome of the Special Meeting in April.
Chairman, President & CEO of Merck & Co Inc (NYSE:MRK) Kenneth C Frazier sold 192,736 shares of MRK on 03/20/2019 at an average price of $82.05 a share.
BERKELEY, Calif. and VANCOUVER, British Columbia, March 20, 2019 -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage.
Not a day goes by that healthcare costs aren't being discussed across each corner of media. With the 2020 election now underway, politicos are ratcheting up the rhetoric over healthcare costs and the political ads are already spinning the topic. And all of this is for good reason. Healthcare costs in the U.S. are high and rapidly rising, especially if you're of retirement age. According to the U.S. Centers for Medicare and Medicaid Services (CMS) -- healthcare spending increased in 2017 by 3.90% to $3.9 trillion or $10,739 per person. This represents 17.90% of the then gross domestic product of the U.S. (GDP). In fact, in a recently published book, More than Medicine: The Broken Promise of American Health by Bob Kaplan, he argues that the U.S. pays way more than its mature economic peers.For example, the U.S. pays 18% of its gross domestic product (GDP) on healthcare whereas the European Union (E.U.) only pays 10% of its combined GDP. And, to make it worse, the U.S. has a lower life expectancy than many nations around the globe. Add in a high poverty rate, which can lead to further health challenges for young and old and other factors showing health troubles, including infant mortality, and the nation doesn't look too healthy. American healthcare may well get even more expensive, as the U.S. ages and becomes less healthy by the day. This isn't a good mix for one of the leading economies of the planet.In a recent study by the U.S. Department of Commerce and the U.S. Census, by 2035, it is projected that 78 million folks will be 65 years or older. That same year, those at or under the age of 18 years will number just 76 million. America is becoming a nation of the elderly -- a significant change in the demographics of a nation traditionally known for its healthy and able folks. It's a shift that leaves many wondering where our economic productivity gains will come from. And, as we know, the elderly population requires the most attentive healthcare … no wonder healthcare spending is climbing.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Stocks on the Rise Heading Into the Second Quarter While this sounds bleak, there is a silver lining here for us as investors. And no, I'm not suggesting that we look at gym companies (although I am poking around at that market with some innovations that I'll be writing about in Profitable Investing in the near future). Rather, I'm suggesting that investing in healthcare stocks that pay dividends is a smart source for capital gains … WP Carey Click to Enlarge Source: Bloomberg One healthcare stock, in particular, comes to mind … I'm referring to WP Carey (NYSE:WPC), which I've written about extensively for InvestorPlace.WP Carey is a REIT, which since coming to the public market, has generated a return of 1,348.28% for an average annual equivalent return of 13.46%. That's not too shabby any way you cut it. The business itself is a curious one: WP Carey doesn't operate its properties, and it doesn't pay for maintenance, insurance, or taxes. Instead, it executes "triple net leases." This means that it locks up long-term cashflows with less risk in rising costs for the properties and the vagrancies of tax rates.Its tenants pay for all of that, thus WP Carey profits from other peoples' money.In the healthcare market, there is a specific equivalent in the following security. Well, this next security is technically a real estate investment trust (REIT) that owns and acquires healthcare facilities including inpatient and outpatient facilities as well as surgical centers and specialty healthcare facilities. Their properties amount to more than 120 properties in 25 states as well as some newer innovative investments in Germany. Scroll down to discover what it is … Medical Properties Trust (MPW) Click to Enlarge Source: Bloomberg Medical Properties Trust (NYSE:MPW) has properties that are leased on a net basis to operators that run the facilities and pay rent month after month for years. The portfolio has expanded dramatically over the recent year with only a small pause in the past year. But it continues to look to expand its portfolio with the right properties in an ever-expanding market.Revenues are climbing with gains running at over 11.30% in just the trailing year. And the funds from operations (FFO) which measures just the return rate from the cashflows from the property portfolio is ample at 11.60%, which is impressive for the REIT space. This contributes to an impressive return on its assets at 11.40% and is what delivers for shareholders with a return on equity of 24.30%.And the stock continues to reflect its performance as a company. Over the past ten years, the stock has delivered a total return of 994.12% for an average annual equivalent of 26.79%. It is a disciplined company when it comes to debt and leverage as its debt to capital is at only 47.00%. This provides the ability to easily service its current debts and provides eased access for credit to fund additional acquisitions. Valued at only 1.49 times its book value, MPW is a steal from a price-book (P/B) perspective. This ratio has climbed significantly over the trailing year, from 1.14 times back in October 2018.But it isn't just the P/B ratio that's rising, but the actual value of the assets. Over the past five years alone, the underlying book value per share has gone from $7.98 to a current $12.27, which represents an impressive gain of 53.76%. This is important as it shows genuine growth in the underlying company and not just the stock price. The dividend is currently at 25 cents per share and has been climbing in distribution by an average annual rate of 4.30% over the past five years. This equates to a current yield of 5.48%. * Top 7 Service Sector Stocks That Will Pay You to Own Them Medical Properties Trust makes for a great buy in the healthcare market (which should be purchased in a taxable account). This is due to the Tax Cuts and Jobs Act (TCJA) which provides a tax deduction of 20% of the dividend distribution for U.S. individual investors making the taxable equivalent yield even higher. Other Stocks to Play HealthcareInside the Profitable Investing model portfolios, I have the overall market for healthcare synthetically invested in the Vanguard Healthcare ETF (NYSEARCA:VHT), which remains a buy in a tax-free account. Then, in my Incredible Dividend Machine portfolio inside Profitable Investing, I have three more plays on healthcare …I have the drugmaker Merck (NYSE:MRK), which continues to perform for shareholders. And I have another drugmaker in Pfizer (NYSE:PFE), which follows the success of Merck. Further, I also have Ventas (NYSE:VTR), which as a real estate investment trust (REIT) that owns a series of senior healthcare and related housing care facilities. VTR is doing quite well with the general REIT sector as we move further into 2019.One of the smartest investment lessons that I learned, from one of my best stocks within Profitable Investing, is to capitalize when the opportunity arises. That is, take risks while you lock in revenues! And the aforementioned stocks should continue to position themselves into the thick of the rising healthcare spending market while paying out an ample and rising dividend.Neil George is the editor of Profitable Investing and does not have any holdings in the securities mentioned above. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Invincible Stocks Leading The Bull Market Higher * 5 Dow Jones Stocks Coming to Life * 7 of the Best High-Yield Funds for 2019 and Beyond Compare Brokers The post Invest in America's Rising Healthcare Costs With These Stocks appeared first on InvestorPlace.
Pfizer (PFE) and Merck KGaA terminate a late-stage study on Bavencio and its new PARP inhibitor, Talzenna. This is the third ovarian cancer study failure in less than six months.
Group Aims to Bring Disease-Associated Biomarker Through FDA’s Drug Development Tools Qualification Program
Merck (MRK), known as MSD outside the United States and Canada, and NGM Biopharmaceuticals, Inc. (NGM) today announced that Merck has exercised its option to extend the research phase of the companies’ broad, strategic collaboration for an additional two-year period from March 2020 to March 2022. The collaboration, originally announced in February 2015, is focused on discovering, developing and commercializing novel biologic therapeutics across a wide range of therapeutic areas.
In a nearly 200-page presentation calling for investors to reject Bristol-Myers Squibb’s proposed acquisition of Celgene released on Monday, activist hedge fund Starboard Value called Celgene’s pipeline of new drugs “unproven.